In particular, SLRPs have a class V member, named podocan-like 1 (PODNL1), which is found to be highly expressed in bone, glioma, bladder and ovarian cancers, representing a potential prognostic biomarker [14,15,16,17,18]. Here, PODNL1 is linked to glioma.